The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Study of Intraventricular Cerliponase Alfa for CLN2 Disease
Abstract
Background Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children. Methods In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with CLN2 disease who were between the ages of 3 and 16 years. Treatment was initiated at a dose of 30 mg, 100 mg, or 300 mg; all the patients then received the 300-mg dose for at least 96 weeks. The primary outcome was the time until a 2-point decline in the score on the motor and language domains of the CLN2 Clinical Rating Scale (which ranges from 0 to 6, with 0 representing no function and 3 representing normal function in each of the two domains), which was compared with the time until a 2-point decline in 42 historical controls. We also compared the rate of decline in the motor-language score between the two groups, using data from baseline to the last assessment with a score of more than 0, divided by the length of follow-up (in units of 48 weeks). Results Twenty-four patients were enrolled, 23 of whom constituted the efficacy population. The median time until a 2-point decline in the motor-language score was not reached for treated patients and was 345 days for historical controls. The mean (±SD) unadjusted rate of decline in the motor-language score per 48-week period…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Precision therapy using intracerebroventricular enzyme replacement with recombinant human tripeptidyl peptidase 1 slowed disease progression in one study 148 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [148]
Citations
Cites
Sleat, D. E., Donnelly, R. J., Lackland, H., Liu, C.-G., Sohar, I., Pullarkat, R. K., & Lobel, P. (1997) · Science · doi:10.1126/science.277.5333.1802 · Cited by 581
NCL diseases - clinical perspectives
Schulz, A., Kohlschütter, A., Mink, J., Simonati, A., & Williams, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.008 · Cited by 246
Self-citationSleat, D. E., Gin, R. M., Sohar, I., Wisniewski, K., Sklower-Brooks, S., Pullarkat, R. K., Palmer, D. N., Lerner, T. J., Boustany, R.-M., Uldall, P., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302427 · Cited by 178
Steinfeld, R., Heim, P., von Gregory, H., Meyer, K., Ullrich, K., Goebel, H. H., & Kohlschütter, A. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10660 · Cited by 178
Self-citationNeurological deterioration in late infantile neuronal ceroid lipofuscinosis
Worgall, S., Kekatpure, M. V., Heier, L., Ballon, D., Dyke, J. P., Shungu, D. C., Mao, X., Kosofsky, B. E., Kaplitt, M. G., Souweidane, M. M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267885.47092.40 · Cited by 112
Self-citationThe Genetic Spectrum of Human Neuronal Ceroid‐lipofuscinoses
Mole, S. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00500.x · Cited by 111
Katz, M. L., Coates, J. R., Sibigtroth, C. M., Taylor, J. D., Carpentier, M., Young, W. M., Wininger, F. A., Kennedy, D., Vuillemenot, B. R., & O'Neill, C. A. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23423 · Cited by 100
Kishnani, P. S., Dickson, P., Muldowney, L., Lee, J. J., Rosenberg, A. S., Abichandani, R., Bluestone, J. A., Burton, B. K., Dewey, M. C., Freitas, A., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.11.001 · Cited by 89
Vuillemenot, B. R., Katz, M. L., Coates, J. R., Kennedy, D., Tiger, P. M. N., Kanazono, S., Lobel, P., Sohár, I., Xu, S., Cahayag, R., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.018 · Cited by 78
Vuillemenot, B. R., Kennedy, D., Cooper, J. D., Wong, A. M. S., Sri, S., Doeleman, T., Katz, M. L., Coates, J. R., Johnson, G. C., Reed, R. P., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.004 · Cited by 60
Research works printed but not linked: 1
- Mole SE, Williams RE, Goebe HH, eds. The neuronal ceroid lipofuscinoses (Batten disease). 2nd ed. Oxford, England: Oxford University Press, 2011.
Cited by
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Neufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Pastores, G. M. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00036-6 · Cited by 633
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489
“Cerliponase alfa treatment has been demonstrated to slow the progressive motor deterioration in CLN2 disease and improve survival (Schulz et al., 2018).”
BackgroundBlood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
The glymphatic system: Current understanding and modeling
Bohr, T., Hjorth, P. G., Holst, S. C., Hrabětová, S., Kiviniemi, V., Lilius, T., Lundgaard, I., Mardal, K.-A., Martens, E. A., Mori, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104987 · Cited by 368
“(Schulz et al., 2018), oligonucleotides (Finkel et al., 2017), and diagnostic agents such as gadoliniumlabeled (Ringstad et al., 2018) and radionuclide-labeled (Verma et al., 2020) CSF tracers.”
Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 290
Riney, K., Bogacz, A., Somerville, E., Hirsch, E., Nabbout, R., Scheffer, I. E., Zuberi, S. M., Alsaadi, T., Jain, S., French, J., et al. (2022) · Epilepsia · doi:10.1111/epi.17240 · Cited by 287
Self-citationLysosomal storage disorders – challenges, concepts and avenues for therapy: beyond rare diseases
Marques, A. R. A., & Saftig, P. (2019) · Journal of Cell Science · doi:10.1242/jcs.221739 · Cited by 224
“However, the recent approval for intraventricular injection with Cerliponase Alfa for the treatment of CNL2 opens up the possibility of expanding ERT to other LSDs with neurological involvement (Schulz et al., 2018).”
BackgroundThe rapidly evolving view of lysosomal storage diseases
Parenti, G., Medina, D. L., & Ballabio, A. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012836 · Cited by 230
“…been proposed for some mucopolysaccharidoses (Giugliani et al, 2018), metachromatic leukodystrophy (I Dali et al, 2020), and is now an approved treatment for neuronal ceroid lipofuscinosis 2, in which intraventricular infusions of cerliponase-alpha reduced disease progression (Schulz et al, 2018).”
BackgroundA Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis
Mole, S. E., Anderson, G., Band, H. A., Berkovic, S. F., Cooper, J. D., Kleine Holthaus, S.-M., McKay, T. R., Medina, D. L., Rahim, A. A., Schulz, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30368-5 · Cited by 206
Self-citationUllman, J. C., Arguello, A., Getz, J. A., Bhalla, A., Mahon, C. S., Wang, J., Giese, T., Bedard, C., Kim, D. J., Blumenfeld, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1163 · Cited by 205
“Currently, a single approved therapy exists to treat a neuronopathic LSD by intracerebroventricular administration, and a clinical trial using intrathecal administration of IDS for treatment of MPS II is underway (54, 55).”
BackgroundTherapeutic landscape for Batten disease: current treatments and future prospects
Johnson, T. B., Cain, J. T., White, K. A., Ramirez-Montealegre, D., Pearce, D. A., & Weimer, J. M. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0138-8 · Cited by 187
Okuyama, T., Eto, Y., Sakai, N., Nakamura, K., Yamamoto, T., Yamaoka, M., Ikeda, T., So, S., Tanizawa, K., Sonoda, H., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.039 · Cited by 183
New epilepsy therapies in development
Klein, P., Kaminski, R. M., Koepp, M. J., & Löscher, W. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00981-w · Cited by 178
“…cerliponase alfa provides effective targeted precision therapy with a notable impact on both seizures and the underlying disease by replacing the missing enzyme tripeptidyl peptidase 1 in the extremely rare genetic disorder of neuronal ceroid lipofuscinosis type 2 or Batten disease 232,233 .”
Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs
Lilius, T. O., Blomqvist, K., Hauglund, N. L., Liu, G., Stæger, F. F., Bærentzen, S., Du, T., Ahlström, F., Backman, J. T., Kalso, E. A., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.005 · Cited by 159
Lysosome biogenesis in health and disease
Bajaj, L., Lotfi, P., Pal, R., Ronza, A. D., Sharma, J., & Sardiello, M. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14564 · Cited by 153
“Fabry disease, Pompe disease and CLN2 disease (Schiffmann et al. 2000; Thurberg et al. 2006; Schulz et al. 2018).”
BackgroundNickel, M., Simonati, A., Jacoby, D., Lezius, S., Kilian, D., Van de Graaf, B., Pagovich, O. E., Kosofsky, B., Yohay, K., Downs, M., et al. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30179-2 · Cited by 148
Self-citationLöscher, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.730257 · Cited by 153
“Based on the pathophysiology of CLN2, recombinant human tripeptidyl peptidase 1 (cerliponase alfa) has been developed as an enzyme replacement to CLN2 (Schulz et al., 2018).”
BackgroundInfluentialGM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
Leal, A. F., Benincore-Flórez, E., Solano-Galarza, D., Garzón-Jaramillo, R. G., Echeverri-Peña, O. Y., Súarez, D. A., Alméciga-Díaz, C. J., & Espejo-Mojica, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176213 · Cited by 141
“The use of several routes such as direct injection into the cerebrospinal fluid and intrathecal or intracerebroventricular (ICV) injections have shown potential therapeutic effects for some LSDs with CNS compromise [14,93,94].”
BackgroundLiu, J., Barrett, J. S., Leonardi, E. T., Lee, L., Roychoudhury, S., Chen, Y., & Trifillis, P. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2134 · Cited by 153
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Developmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
“Precision therapy using intracerebroventricular enzyme replacement with recombinant human tripeptidyl peptidase 1 slowed disease progression in one study 148 .”
Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses
Kohlschütter, A., Schulz, A., Bartsch, U., & Storch, S. (2019) · CNS Drugs · doi:10.1007/s40263-019-00620-8 · Cited by 133
Self-citationWu, J., Wang, C., Toh, S., Pisa, F. E., & Bauer, L. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4962 · Cited by 121
Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app
van Konijnenburg, E. M. M. H., Wortmann, S. B., Koelewijn, M. J., Tseng, L. A., Houben, R. F. A., Stöckler‐Ipsiroglu, S., Ferreira, C. R., & van Karnebeek, C. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01727-2 · Cited by 126
Identifying mutations in epilepsy genes: Impact on treatment selection
Perucca, P., & Perucca, E. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.03.001 · Cited by 131
Marques, A. R. A., Spiezio, A. D., Thießen, N., Schmidt, L., Grötzinger, J., Lüllmann‐Rauch, R., Daμμe, M., Storck, S. E., Pietrzik, C. U., Fogh, J. M., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1637200 · Cited by 104
“This strategy has recently been expanded to peptidases and NCLs with the approval of Brineura (cerliponase alfa) for the treatment of CLN2 patients by intraventricular injection every 15 d [16].”
BackgroundMethodInfluentialImpact of predictive, preventive and precision medicine strategies in epilepsy
Nabbout, R., & Kuchenbuch, M. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0409-4 · Cited by 113
Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses
Mukherjee, A. B., Appu, A. P., Sadhukhan, T., Casey, S., Mondal, A., Zhang, Z., & Bagh, M. B. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0300-6 · Cited by 110
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues
Naseri Kouzehgarani, G., Feldsien, T., Engelhard, H. H., Mirakhur, K. K., Phipps, C., Nimmrich, V., Clausznitzer, D., & Lefebvre, D. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.002 · Cited by 95
McKnight, D., Morales, A., Hatchell, K. E., Bristow, S. L., Bonkowsky, J. L., Perry, M. S., Berg, A. T., Borlot, F., Esplin, E. D., Moretz, C., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3651 · Cited by 98
Drobny, A., Huarcaya, S. P., Dobert, J. P., Kluge, A., Bunk, J., Schlothauer, T., & Zunke, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119243 · Cited by 104
Moreira, R., Nóbrega, C., de Almeida, L. P., & Mendonça, L. S. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02511-7 · Cited by 102
“These limitations, and complications related to the devices, namely severe infections, leakage, and immune system activation (presence of white cells in the CSF), have reduced the use of this strategy for brain therapies [63, 70].”
BackgroundRecombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models
Huarcaya, S. P., Drobny, A., Marques, A. R. A., Spiezio, A. D., Dobert, J. P., Balta, D., Werner, C. D., Rizo, T., Gallwitz, L., Bub, S., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2045534 · Cited by 104
“Currently, intraventricular infusion for the treatment of the LSD CLN type 2 (CLN2) is in clinical trials [106].”
BackgroundNeuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview
Simonati, A., & Williams, R. E. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.811686 · Cited by 106
“As for its efficacy there is good evidence that disease progression is slowed down over a 4 year period, as compared with historical untreated controls (174, 175).”
BackgroundJensen, T. L., Gøtzsche, C. R., & Woldbye, D. P. D. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.695937 · Cited by 102
Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways
Cano, A. C., Fonseca, E., Ettcheto, M., Sánchez‐López, E., de Rojas, I., Alonso-Lana, S., Morató, X., Souto, E. B., Toledo, M., Boada, M., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14101057 · Cited by 94
“Advances in the knowledge of the genetics and pathophysiology of some specific diseases associated with epilepsy have led to the development of specific treatments for some syndromes, such as everolimus in tuberous sclerosis complex [103] or lysosomal enzyme replacement in neuronal ceroid lipofuscinosis [104].”
BackgroundThe best evidence for progressive myoclonic epilepsy: A pathway to precision therapy
Orsini, A. A., Valetto, A., Bertini, V., Esposito, M., Carli, N., Minassian, B. A., Bonuccelli, A., Peroni, D. G., Michelucci, R., & Striano, P. (2019) · Seizure · doi:10.1016/j.seizure.2019.08.012 · Cited by 89
“NCLs are considered as lysosomal storage diseases (LSDs), however many distinct characteristics are observed.”
BackgroundInfluentialEnzyme replacement therapy for mucopolysaccharidoses; past, present, and future
Chen, H. H., Sawamoto, K., Mason, R. W., Kobayashi, H., Yamaguchi, S., Suzuki, Y., Orii, K. E., Orii, T., & Tomatsu, S. (2019) · Journal of Human Genetics · doi:10.1038/s10038-019-0662-9 · Cited by 80
Gardner, E., Bailey, M., Schulz, A., Aristorena, M., Miller, N., & Mole, S. (2019) · Human Mutation · doi:10.1002/humu.23860 · Cited by 75
“Early diagnosis has become even more relevant as a recently approved intracerebroventricular enzyme replacement therapy has been shown to effectively slow the rapid decline in motor and language function in patients with CLN2 disease (Schulz et al., 2018).”
BackgroundSelf-citationSondhi, D., Kaminsky, S. M., Hackett, N. R., Pagovich, O. E., Rosenberg, J. B., De, B. P., Chen, A., Van de Graaf, B., Mezey, J. G., Mammen, G. W., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5413 · Cited by 72
“If the gene therapy could be improved, the theoretical advantage is that it could potentially be efficacious with a single administration, whereas the recombinant TPP1 therapy requires administration every other week (31, 40, 41).”
BackgroundSelf-citationThe Genetic Basis of Phenotypic Heterogeneity in the Neuronal Ceroid Lipofuscinoses
Gardner, E., & Mole, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.754045 · Cited by 77
“This is increasing understanding of the genetic spectrum of NCL disease as well as provide necessary control data for use in future clinical trials (77).”
BackgroundMulberg, A. E., Bucci-Rechtweg, C. M., Giuliano, J. D., Jacoby, D. R., Johnson, F. K., Liu, Q., Marsden, D., McGoohan, S., Nelson, R. M., Patel, N., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1017-5 · Cited by 72
Self-citationNeuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy
Specchio, N., Ferretti, A., Trivisano, M., Pietrafusa, N., Pepi, C., Calabrese, C., Livadiotti, S., Simonetti, A., Rossi, P., Curatolo, P., et al. (2020) · Drugs · doi:10.1007/s40265-020-01440-7 · Cited by 77
Self-citationScheffer, I. E., French, J. A., Valente, K. D. R., Auvin, S., Cross, J. H., & Specchio, N. (2025) · Epilepsia · doi:10.1111/epi.18265 · Cited by 72
“24 Such trials have different challenges in their design, such as how long a drug should be administered in n- of-1 studies to realistically show cognitive gains.”
Self-citationBerg, A. T., Levy, S. R., & Testa, F. M. (2018) · Epilepsia · doi:10.1111/epi.14569 · Cited by 68
“Its availability has spurred efforts to diagnose affected children at the time of the first presentation with epilepsy before all of the features of the disease are apparent, obtain a genetic diagnosis, and proceed to therapy immediately.(41) In light of all of the work done on other extremely rare and devastating con…”
BackgroundCNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges
Edelmann, M. J., & Maegawa, G. H. B. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.559804 · Cited by 71
“Serious adverse events included the failure of the intraventricular device and device-related infections (Schulz et al., 2018).”
BackgroundMole, S., Schulz, A., Badoe, Ë., Berkovic, S. F., Reyes, E. D. L., Dulz, S., Gissen, P., Guelbert, N. B., Lourenço, C. M., Mason, H., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01813-5 · Cited by 68
Self-citationThe expanding spectrum of movement disorders in genetic epilepsies
Papandreou, A., Danti, F. R., Spaull, R., Leuzzi, V., McTague, A., & Kurian, M. A. (2019) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14407 · Cited by 70
Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses
Butz, E. S., Chandrachud, U., Mole, S. E., & Cotman, S. L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165571 · Cited by 62
From molecules to medicines: the dawn of targeted therapies for genetic epilepsies
Demarest, S., & Brooks‐Kayal, A. R. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0099-3 · Cited by 64
Improving epilepsy diagnosis across the lifespan: approaches and innovations
Pellinen, J., Foster, E., Wilmshurst, J. M., Zuberi, S. M., & French, J. A. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00079-6 · Cited by 66
Wright, G., Georgiou, M., Robson, A. G., Ali, N., Kalhoro, A., Holthaus, S.-M. K., Pontikos, N., Oluonye, N., de Carvalho, E. R., Neveu, M. M., et al. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.11.005 · Cited by 59
Schulz, A., Specchio, N., Reyes, E. D. L., Gissen, P., Nickel, M., Trivisano, M., Aylward, S. C., Chakrapani, A., Schwering, C., Wibbeler, E., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00384-8 · Cited by 59
Self-citationDíaz‐Caneja, C. M., State, M. W., Hagerman, R. J., Jacquemont, S., Marín, Ó., Bagni, C., Umbricht, D., Simonoff, E. A., Andres-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 59
Berg, A. T., Palac, H., Wilkening, G. N., Zelko, F. A. J., & Schust, L. F. (2020) · Epilepsia · doi:10.1111/epi.16750 · Cited by 60
Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
Specchio, N., Pietrafusa, N., & Trivisano, M. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s241048 · Cited by 54
Self-citationBerg, A. T., Gaebler-Spira, D. J., Wilkening, G. N., Zelko, F. A. J., Knupp, K. G., Dixon‐Salazar, T., Villas, N., Meskis, M. A., Harwell, V., Thompson, T., et al. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107287 · Cited by 59
Palmer, E. E., Howell, K., & Scheffer, I. E. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01133-3 · Cited by 53
From next-generation sequencing to targeted treatment of non-acquired epilepsies
Møller, R. S., Hammer, T. B., Rubboli, G., Lemke, J. R., & Johannesen, K. M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1573144 · Cited by 60
“A recent study on 24 children with CLN2 has shown that intraventricular infusion of cerliponase alfa (a recombinant proenzyme of TPP1) results in less decline in motor and language function compared to historical controls [141].”
Lysosome (Dys)function in Atherosclerosis—A Big Weight on the Shoulders of a Small Organelle
Marques, A. R. A., Ramos, C., Machado-Oliveira, G., & Vieira, O. V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.658995 · Cited by 55
Succinic Semialdehyde Dehydrogenase Deficiency: An Update
Didiasova, M., Banning, A., Brennenstuhl, H., Jung-Klawitter, S., Cinquemani, C., Opladen, T., & Tikkanen, R. (2020) · Cells · doi:10.3390/cells9020477 · Cited by 52
“This route of delivery is used in the case of Cerliponase alfa (Brineura®), the recombinant enzyme used in cLINCL [101].”
MethodNovel therapies for epilepsy in the pipeline
Mesraoua, B., Deleu, D., Kullmann, D. M., Shetty, A. K., Boon, P., Perucca, E., Mikati, M. A., & Asadi‐Pooya, A. A. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.042 · Cited by 54
Landmark, C. J., Potschka, H., Auvin, S., Wilmshurst, J. M., Johannessen, S. I., Trenité, D. G. A. K.-N., & Wirrell, E. C. (2021) · Epilepsia · doi:10.1111/epi.16849 · Cited by 51
An Adapted Clinical Measurement Tool for the Key Symptoms of CLN2 Disease
Wyrwich, K. W., Schulz, A., Nickel, M., Slasor, P., Ajayi, T., Jacoby, D. R., & Kohlschütter, A. (2018) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1177/2326409818788382 · Cited by 51
“(cerliponase alfa), a recombinant form of TPP1, has been developed as a treatment for CLN2 disease.(7) Cerliponase alfa”
Self-citationThe future of newborn screening for lysosomal disorders
Wasserstein, M., Orsini, J. J., Goldenberg, A. J., Caggana, M., Levy, P. A., Breilyn, M. S., & Gelb, M. H. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136080 · Cited by 45
Aberrant upregulation of the glycolytic enzyme PFKFB3 in CLN7 neuronal ceroid lipofuscinosis
López-Fabuel, I., Macia, M. G., Buondelmonte, C., Burmistrova, O., Bonora, N., Alonso-Batan, P., Morant-Ferrando, B., Vicente‐Gutiérrez, C., Jiménez-Blasco, D., Quintana–Cabrera, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28191-1 · Cited by 43
Warmerdam, H. A. G., Ferreira, E. A., Tseng, L. A., Lee, J. Y., van Eeghen, A. M., Ferreira, C. R., & van Karnebeek, C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01369 · Cited by 41
Advances in the treatment of neuronal ceroid lipofuscinosis
Rosenberg, J. B., Chen, A., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1684258 · Cited by 44
“a 300 mg dose every other week, with drug delivery accomplished using a surgically-implanted ventricular reservoir and catheter [220].”
BackgroundMethodInfluentialSleat, D. E., Wiseman, J. A., El-Banna, M., Zheng, H., Zhao, C., Soherwardy, A., Moore, D. F., & Lobel, P. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001587 · Cited by 42
“We have therefore focused on CSF as a biological fluid that is proximal to the brain which is also relatively accessible, especially in LINCL patients undergoing CSFmediated enzyme replacement therapy (2).”
BackgroundMethodFDA orphan drug designations for lysosomal storage disorders – a cross-sectional analysis
Garbade, S. F., Zielonka, M., Mechler, K., Kölker, S., Hoffmann, G. F., Staufner, C., Mengel, E., & Ries, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230898 · Cited by 44
“While alglucerase for Gaucher disease was the first orphan drug approved for a lysosomal storage disease in 1991, intrathecally administered cerliponase alfa for CLN2, FDA approved in 2017, is the first orphan drug for a lysosomal storage disorder to directly treat the brain, which is a significant therapeutic innovat…”
BackgroundHolthaus, S.-M. K., Aristorena, M., Maswood, R. N., Semenyuk, O., Hoke, J., Hare, A., Smith, A. J., Mole, S., & Ali, R. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.038 · Cited by 41
Johnson, T. B., White, K. A., Brudvig, J. J., Cain, J. T., Langin, L. M., Pratt, M. A., Booth, C. D., Timm, D. J., Davis, S. S., Meyerink, B. L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.033 · Cited by 39
Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement
Sevin, C., & Deiva, K. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.624988 · Cited by 44
“On the other hand, encouraging results were obtained after the intracerebroventricular administration of recombinant enzyme in patients with CLN2 disease, if treated at an early stage of their disease (Schulz et al., 2018).”
BackgroundPardridge, W. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114234 · Cited by 44
Kaminiów, K., Kozak, S., & Paprocka, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105729 · Cited by 45
Enzyme therapy: a forerunner in catalyzing a healthy society?
Datta, S., Rajnish, K. N., Doss, C. G. P., Samuel, S. M., Ethiraj, S., & Zayed, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1787980 · Cited by 38
Seo, J.-H., Kosuga, M., Hamazaki, T., Shintaku, H., & Okuyama, T. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.018 · Cited by 38
A multi-disciplinary clinic for SCN8A-related epilepsy
Schreiber, J. M., Tochen, L. S., Brown, M., Evans, S. H., Ball, L. J., Bumbut, A., Thewamit, R., Whitehead, M. T., Black, C. L., Boutzoukas, E. M., et al. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.106261 · Cited by 42
From Lysosomal Storage Disorders to Parkinson’s Disease – Challenges and Opportunities
Mächtel, R., Boros, F. A., Dobert, J. P., Arnold, P., & Zunke, F. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167932 · Cited by 39
Cherukuri, A., Cahan, H., de Hart, G., Tuyl, A. V., Slasor, P., Bray, L., Henshaw, J., Ajayi, T., Jacoby, D., O’neill, C. A., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.09.003 · Cited by 36
Self-citationLewis, G., Morrill, A. M., Conway-Allen, S. L., & Kim, B. (2019) · Journal of Child Neurology · doi:10.1177/0883073819895694 · Cited by 35
“In an open-label, multicenter study, the safety and efficacy of intracerebroventricular infusions of cerliponase alfa every 2 weeks in children between the ages of 3 and 16 years with neuronal ceroid lipofuscinosis type 2 disease were evaluated.(10) To be eligible for inclusion, patients must have had combined scores…”
BackgroundMethodResultInfluentialDoccini, S., Morani, F., Nesti, C., Pezzini, F., Calza, G., Soliymani, R., Signore, G., Rocchiccioli, S., Kanninen, K. M., Huuskonen, M. T., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0250-y · Cited by 35
Cathepsin D: Analysis of its potential role as an amyloid beta degrading protease
Gallwitz, L., Schmidt, L., Marques, A. R. A., Tholey, A., Cassidy, L., Ulku, I., Multhaup, G., Spiezio, A. D., & Säftig, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105919 · Cited by 38
Management of CLN1 Disease: International Clinical Consensus
Augustine, E. F., Adams, H., Reyes, E. D. L., Drago, K., Frazier, M., Guelbert, N. B., Laine, M., Levin, T., Mink, J. W., Nickel, M., et al. (2021) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2021.04.002 · Cited by 41
Self-citationTherapeutic Strategies For Tay-Sachs Disease
Picache, J. A., Zheng, W., & Chen, C. Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906647 · Cited by 35
“Direct CNS administrations of ERT have also been tested in a few LSDs via intrathecal injection for Hurler syndrome (Akeboshi et al., 2007) andMPS I (Concolino et al., 2018; Chen et al., 2020), and intraventricular infusion for neuronal ceroid lipofuscinosis type 2 (CLN2) (Schulz et al., 2018).”
BackgroundThe contribution of multicellular model organisms to neuronal ceroid lipofuscinosis research
Huber, R. J., Hughes, S. M., Liu, W., Morgan, A., Tuxworth, R. I., & Russell, C. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165614 · Cited by 36
Amadori, E., Scala, M., Cereda, G. S., Vari, M. S., Marchese, F., Pisa, V. D., Mancardi, M. M., Giacomini, T., Siri, L., Vercellino, F., et al. (2020) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-020-00860-1 · Cited by 37
Intrathecal delivery and its applications in leptomeningeal disease
Khang, M., Bindra, R. S., & Saltzman, W. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114338 · Cited by 34
Sonoda, H., Takahashi, K. P., Minami, K., Hirato, T., Yamamoto, T., So, S., Tanizawa, K., Schmidt, M., & Sato, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061240 · Cited by 33
“For intra-CSF administration of therapeutic enzymes, the ICV route has proved viable, as exemplified by cerliponase alfa for the treatment of neuronal ceroid lipofuscinosis type 2 [19,20] and idursulfase beta for mucopolysaccharidosis II (MPS II, Hunter syndrome) [21].”
MethodThe collective burden of childhood dementia: a scoping review
Elvidge, K. L., Christodoulou, J., Farrar, M. A., Tilden, D., Maack, M., Valeri, M., Ellis, M. K., Smith, N. J. C., the Childhood Dementia Working Group, Thorburn, D. R., et al. (2023) · Brain · doi:10.1093/brain/awad242 · Cited by 33
“It has been shown to slow progression of motor and language deficits 53 although no long-term studies have been performed to date.”
BackgroundHoffmann, F. D., Hoffmann, S., Kunzmann, K., & Ries, M. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01548-9 · Cited by 32
Videnović, A., Pfeiffer, H. C. V., Tylki‐Szymańska, A., Berry‐Kravis, E., Ezgü, F. S., Ganju, J., Jurecka, A., & Lang, A. E. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1098454 · Cited by 31
“70) and neuronal ceroid lipofuscinosis 2 (CLN2) (57).”
BackgroundMethodInfluentialEstublier, B., Cano, A., Hoebeke, C., Pichard, S., Scavarda, D., Desguerre, I., Auvin, S., & Chabrol, B. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2020.12.002 · Cited by 32
Real-World Evidence for Assessing Treatment Effectiveness and Safety in Pediatric Populations
Horton, D. B., Blum, M. D., & Burcu, M. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.06.062 · Cited by 31
“For example, cerliponase alfa was approved as a treatment for a rare pediatric lysosomal disorder (neuronal ceroid lipofuscinosis type 2 disease) following a single-arm study, which used a natural-history RWD external control.(10,11) As another example of RWE supporting pediatric drug approvals, blinatumomab was appro…”
Berg, A. T., Kaat, A. J., Zelko, F. A. J., & Wilkening, G. N. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108586 · Cited by 31
Neuronal ceroid lipofuscinosis type 2: an Australian case series
Johnson, A., Mandelstam, S. A., Andrews, I., Boysen, K. E., Yaplito‐Lee, J., Fietz, M., Nagarajan, L., Rodriguez‐Casero, V., Ryan, M. M., Smith, N. J. C., et al. (2020) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.14890 · Cited by 31
Lourenço, C. M., Pessoa, A. L. S., Mendes, C. S. C., Rivera‐Nieto, C., Vergara, D., Troncoso, M., Gardner, E., Mallorens, F., Tavera-Saldaña, L. M., Lizcano, L. A., et al. (2020) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.15250 · Cited by 33
Metadata
- Authors
- Schulz, A., Ajayi, T., Specchio, N., de Los Reyes, E., Gissen, P., Ballon, D., Dyke, J. P., Cahan, H., Slasor, P., Jacoby, D., & Kohlschütter, A.
- Affiliations
- Nationwide Children's Hospital (US)
- From the Department of Pediatrics, University Medical Center Hamburg–Eppendorf, Hamburg, Germany (A.S., A.K.); BioMarin Pharmaceutical, Novato, CA (T.A., H.C., P.S., D.J.); the Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome (N.S.); Nationwide Children’s Hospital and Ohio State University, Columbus (E.L.R.); UCL Great Ormond Street Institute of Child Health, London (P.G.); and the Citigroup Biomedical Imaging Center, Departments of Radiology and Genetic Medicine, Weill...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-17
- Volume
- 378
- Issue
- 20
- Pages
- 1898-1907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2799850385
- Cited by
- 489
- References
- 17
- Citations by year
- 2026: 36 · 2025: 57 · 2024: 37 · 2023: 49 · 2022: 86 · 2021: 74 · 2020: 83 · 2019: 47 · 2018: 17
- FWCI
- 37.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health Research
- European Union Seventh Framework Program Grand (281234)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- cerliponase alfa, CLN2 disease, neuronal ceroid lipofuscinosis type 2, intraventricular infusion, enzyme replacement therapy, tripeptidyl peptidase 1, lysosomal storage disease, pediatric patients, device-related infection, adverse events
- MeSH terms
- Tripeptidyl-Peptidase 1, Adolescent, Child, Child, Preschool, Dementia, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Female, Humans, Language Development, Male, Motor Skills, Neuronal Ceroid-Lipofuscinoses, Recombinant Proteins, Disease Progression, Kaplan-Meier Estimate, Enzyme Replacement Therapy, Infusions, Intraventricular, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.